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Abstract: 
 
A number of distinct viruses are known as hemorrhagic fever viruses based on a shared ability to 
induce hemorrhage by poorly understood mechanisms, typically involving the formation of 
blood clots (“disseminated intravascular coagulation”). It is well documented that selenium plays 
a significant role in the regulation of blood clotting via its effects on the 
thromboxane/prostacyclin ratio, and effects on the complement system. Selenium has an 
anticlotting effect, whereas selenium deficiency has a proclotting or thrombotic effect. It is also 
well documented that extreme dietary selenium deficiency, which is almost never seen in 
humans, has been associated with hemorrhagic effects in animals. Thus, the possibility that viral 
selenoprotein synthesis might contribute to hemorrhagic symptoms merits further consideration. 
Computational genomic analysis of certain hemorrhagic fever viruses reveals the presence of 
potential protein coding regions (PPCRs) containing large numbers of in-frame UGA codons, 
particularly in the −1 reading frame. In some cases, these clusterings of UGA codons are very 
unlikely to have arisen by chance, suggesting that these UGAs may have some function other 
than being a stop codon, such as encoding selenocysteine. For this to be possible, a downstream 
selenocysteine insertion element (SECIS) is required. Ebola Zaire, the most notorious 
hemorrhagic fever virus, has a PPCR with 17 UGA codons, and several potential SECIS 
elements can be identified in the viral genome. One potential viral selenoprotein may contain up 
to 16 selenium atoms per molecule. Biosynthesis of this protein could impose an unprecedented 
selenium demand on the host, potentially leading to severe lipid peroxidation and cell membrane 
destruction, and contributing to hemorrhagic symptoms. Alternatively, even in the absence of 
programmed selenoprotein synthesis, it is possible that random slippage errors would lead to 
increased encounters with UGA codons in overlapping reading frames, and thus potentially to 
nonspecific depletion of SeC in the host. 
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Article: 
 
INTRODUCTION 
 
Hemorrhagic manifestations are the main pathophysiological features of all hemorrhagic fever 
diseases. The viruses causing hemorrhagic fevers in humans belong to the following groups: 
togavirus (Chikungunya), flavivirus (Dengue, Yellow fever, Kyansanu forest disease, Omsk 
hemorrhagic fever), arenavirus (Argentinean hemorrhagic fever, Bolivian hemorrhagic fever, 
Lassa fever), filovirus (Ebola, Marburg), phlebovirus (Rift Valley fever), nairovirus (Crimian-
Congo Hemorrhagic fever) and hantavirus (hemorrhagic fever with renal syndrome, 
nephropathic epidemia) (1). Filovirus infections have several pathological features common with 
other severe viral hemorrhagic fevers (2). Among these viruses, filoviruses cause one of the 
highest fatality rates and the most severe hemorrhagic manifestations (3,4). The 
pathophysiological events that make the filovirus infections of humans so devastating are still 
obscure. The viruses are pantropic, but no single organ shows sufficient damage to account for 
either the onset of the severe shock syndrome or the bleeding conditions (5). Ebola virus (Zaire 
strain), the most lethal filovirus, will be studied in this communication. Since hemorrhagic 
conditions are the main feature, an analysis of the various mechanism by which hemorrhage can 
occur can give some clue to the viral pathogenesis. 
 
MECHANISMS OF HEMORRHAGE FORMATION 
 
Hemorrhage can occur by several mechanisms, which may be interrelated. One is the 
dysfunction and damage of endothelial cells, which form the inner surface of blood vessels and 
play a role in the regulation of blood pressure, homeostasis, and antithrombogenicity. 
Endothelial cell lysis is observed in the development of shock lung syndrome often associated 
with disseminated intravascular coagulation (DIC) (6,7). It has been shown that Marburg virus 
replicates in endothelial cells, but there is no direct experimental evidence that links the 
hemorrhagic manifestations to the vitally induced damage to the endothelial cells (8). Hantaan 
virus has also been shown to replicate in endothelial cells (9). Another mechanism is 
hemorrhagic conditions induced by complement activation (10). Extensive complement 
activation precedes onset of shock in Dengue patients (11). 
 
Another fundamental mechanism in the production of DIC is via the formation of blood clots 
(12). The severe hemorrhaging produced by Ebola virus is essentially owing to the formation of 
blood clots--the "coagulation" of DIC--which leads to the obstruction and rupture of small blood 
capillaries. Thus, the hemorrhagic symptoms may be in large part a consequence of clot 
formation. 
 
SELENIUM AND HEMORRHAGIC CONDITIONS 
 
Significantly, it is well documented that selenium plays a major role in the regulation of blood 
clotting via its effects on the thromboxane and prostacyclin ratio (13,14). Prostacyclin (PG12) 
and thromboxane (TXA2) are eicosanoids metabolites of arachidonic acid, and are involved in 
controlling platelet activity and vascular tone. PG12 is synthesized by both endothelial and 
vascular smooth muscle cells, and is both a potent vasodilator and an endogenous inhibitor of 
platelet aggregation (15-17). Conversely, TXA2, produced mainly by blood platelets, behaves as 
a vasoconstrictor and promotes platelet aggregation (18,19). The equilibrium between the 
production of arterial wall PG12 and platelet TXA2 has been suggested to be an important factor 
in platelet activity and aggregation. Thus, an increase in the PG12/TXA2 ratio will tend to inhibit 
clotting. 
 
Selenium enhances glutathione peroxidase (GSH-Px) activity and prostacyclin release in cultured 
human endothelial cells, the very cell types that have been implicated in the pathogenesis of 
some hemorrhagic fevers (13). It has been reported that there is an increased PG12 production 
with selenium supplementation, whereas there is decreased aortic synthesis of prostacyclin-like 
compounds in selenium-deficient rats (20,21). An increase in TXA2 synthesis by rat lung 
neutrophils was observed during selenium deficiency (22). Increased bleeding time resulting 
from selenium supplementation has been observed owing to the increased GSH-Px activity, 
favoring PG12 over TXA2 formation (20). In a human study, selenium supplementation 
inhibited in vitro and in vivo production of TXA2, whereas PG12 synthesis was unaffected (23). 
Clearly, the net effect of selenium supplementation is an increased PG12/TXA2 ratio, which will 
inhibit clot formation. Thus, one would expect selenium to tend to reduce DIC, and the 
associated hemorrhagic symptoms. Conversely, any virally induced selenium depletion (at this 
point hypothetical) could favor hemorrhagic conditions. 
 
This mechanism is supported by extensive documentation of hemorrhagic symptoms associated 
with extreme selenium deficiency. Pathological examination of pigs fed on a selenium-deficient 
diet showed liver necrosis, exudative diathesis, hemorrhages, and ulcers of the stomach, with 
hemorrhages and inflammation of the mucosa of the colon (24). Mulberry heart disease, which is 
characterized by hemorrhagic changes particularly in the myocardium and epicardium, was 
observed in a group of piglets with a severe selenium deficiency (25). Pathological examination 
of chicks revealed hemorrhagic conditions with large amounts of blue-greenish fluid under the 
skin (26). Similar hemorrhagic conditions have been seen in goats, elk, and lamb when fed on a 
selenium-deficient diet (27-29). Thus, both biochemical and in vivo studies show that selenium 
deficiency or selenium depletion can lead to hemorrhagic manifestations, probably via a 
proclotting mechanism. 
 
These observations suggest that selenium might also be involved in the hemorrhagic 
manifestations seen in hemorrhagic viral diseases. If so, selenium could act by various 
mechanisms, either by exerting its effects in endothelial cells, on complement activation, or by 
affecting the PG12/TXA2 ratio and thus blood clotting. A significant role for selenium appears 
to be strongly supported by the results of Hou and coworkers, who treated victims of an Asian 
outbreak of viral hemorrhagic fever with high-dose oral sodium selenite, obtaining dramatic 
reductions in mortality (30). Although Hou et al. focused on complement activation as a probable 
mechanism of action, the possibility that this treatment also helped to counter a virally induced 
selenium depletion merits consideration in the light of the viral selenoprotein theory (31) and our 
recent demonstration of UGA-rich potential protein coding regions (PPCRs) in Ebola virus (32). 
 
POSSIBLE MECHANISMS FOR VIRALLY INDUCED SELENIUM DEPLETION 
 
As discussed in the accompanying article (31), there are at least two possible mechanisms by 
which selenium might be incorporated into viral proteins, and both are still hypothetical at the 
present time. The first is nonspecific selenoprotein formation associated with random 
translational slippage into UGA-rich overlapping reading frames, and the second is the 
possibility of specific virally encoded selenoproteins biosynthesized under the direction of RNA 
stem-loop structures. 
 
Viruses are known to frameshift randomly at low frequency, leading to erroneous translational 
slippage into other frames. Rima has suggested that it may be advantageous for viruses to have a 
high density of stop codons in the overlapping frames, so that a ribosome that had slipped 
erroneously would stop quickly, conserving cellular resources (33). However, instead of a 
random distribution of stop codons, he noted a bias in the distribution of stop codons in RNA 
viruses. In paramyxoviruses, there are up to three times the expected number of UGA codons in -
1 frame, and up to 1.5 times the expected number of UAG codons in the +1 frame in some genes 
(33). Consistent with Rima's observations, in many RNA viruses, we have noted a bias in favor 
of UGA codons in the overlapping reading frames, particularly the -1 frame, exemplified here by 
our analyses of rabbit hemorrhagic disease virus, Hantaan virus, and Ebola (Figs. 1 and 2). The 
rationale for how random slippage errors would lead to increased encounters with UGA codons, 
and thus potentially to nonspecific incorporation of selenocysteine (SeC), is discussed eleswhere 
(31). By this mechanism, even though the virus is not programmed to make selenoproteins, it is 
possible that under specific conditions, probably related to the severity of the infection, this 
process might lead to a nonspecific depletion of selenium in the host. 
 
 
Fig. 1. Schematic figure of the complete genome of rabbit hemorrhagic fever virus (RHFV) 
(Genbank accession Z29514) and Haantan virus polymerse gene (Genbank accession X55901), 
translated in all three reading frames. The dotted lines represent UGA codons and the solid 
vertical lines represent non-UGA stop codons (UAA and UAG). This analysis is the first step in 
the general computational strategy for prediction of potential selenoprotein genes. Note the 
exceptionally high content of UGA codons relative to non-UGA stop codons in both overlapping 
frames for RHFV, and in the -1 frame for Hantaan virus (see text for discussion). 
 
 
Fig. 2. Presence of UGA-rich PPCRs overlapping the Ebola Zaire nucleoprotein (NP) coding 
region. The figure shows a schematic of the three reading frames for a portion of the NP gene 
(see legend to Fig. 1). The dotted lines are UGA stop codons, which can potentially encode 
selenocysteine. There are two UGA-rich PPCRs -1 to the main NP reading flame, PPCR1 with 
17, and PPCR2 with 11 in-frame UGA codons. Neither PPCR1 nor PPCR2 has a start codon. 
PPCR1 could be expressed as an NP fusion protein containing a selenoprotein module, by means 
of a frameshift at either one of two potential -1 frameshift sites, shown with an arrow symbol as 
A and B (shown in detail in Fig. 3). The alternate possibility of random nonspecific 
selenocysteine incorporation consequent to erroneous translation frameshifts into these regions is 
discussed in the text. 
 
Alternatively, we find that in some cases these UGA-rich overlapping reading frames are 
associated with potential -1 frameshift sites (31,32,34), including potential RNA pseudoknots 
that are typically required for the enhancement of frameshifting efficiency (35). This suggests 
that there could be programmed synthesis of specific selenoproteins in such cases, which would 
require some type of SeC insertion element, an RNA stem-loop structure, somewhere in the viral 
mRNA (36). 
 
As detailed in the accompanying paper (31), selenoproteins are formed by the translation of 
UGA as SeC, rather than its normal role as a stop codon. The possibility that UGA codons can be 
translated as SeC thus creates new PPCRs, which would be neglected in a conventional protein 
translation. 
 
We have previously demonstrated the potential for selenoproteins to be encoded in regions 
overlapping known genes in HIV-1 (31,34,37,38), Coxsackie virus B3 (31,38), and Ebola virus 
(32). In each case, the link between Se deficiency and the associated viral diseases (AIDS, viral 
myocarditis, and hemorrhagic conditions, respectively) is supported by an extensive body of 
literature (34,39-41). 
 
COMPUTATIONAL APPROACH FOR THE IDENTIFICATION OF POTENTIAL 
SELENOPROTEIN CODING REGIONS 
 
A viral genomic sequence is translated in all the three frames using a modified translation table 
to distinguish the various stop codons. The PPCRs rich in UGA codons are analyzed for the 
presence of a start codon. If there is no start codon, it is possible that there could be a frameshift 
from the main frame into the UGA-rich frame (usually a -1 shift). This requires a frameshift 
sequence, ideally an XXXYYYZ heptamer, but reasonable deviations from this or tetramers 
suitable for P-site slippage may also function. If such a suitably located site is found, there 
should be an RNA stem-loop or pseudoknot (PK) just downstream of the frameshift site. 
Theoretically, a novel PPCR can also be expressed by being linked in-frame to an expressed 
ORF by splicing. For splicing to play a role, transcription in the nucleus would have to occur, 
and appropriately located splice donor and splice acceptor sites identified in the sequence. The 
virus can also potentially switch between frames via RNA editing; the sequence signals required 
for this are not very well characterized, and may be difficult to identify. Finally, for a UGA 
codon to be translated as SeC, a characteristic step-loop structure called a SeC insertion sequence 
or an SECIS element is required (36). Candidate sequences having the consensus sequences 
features of an SECIS element are examined for potential to form the necessary RNA stem-loop 
structures, using the Zuker FOLD program (42). 
 
If candidate selenoprotein or other genes are identified, the hypothetical protein sequence can be 
compared to known sequences in a protein data base in order to find potentially homologous 
known proteins. The data base search can be done using a program, such as FASTA, e.g., as 
implemented in the GCG software package (Program Manual for the Wisconsin Package, Ver. 8, 
September 1994, Genetics Computer Group, 575 Science Drive, Madison, WI 53711). 
 
COMPUTATIONAL GENOMIC ANALYSIS OF EBOLA VIRUS 
 
We recently reported theoretical molecular evidence that the highly pathogenic Zaire strain of 
the Ebola virus may be dependent on selenium owing to the presence of several PPCRs in the 
Ebola genome containing clusters of up to 17 in-frame UGA codons (32). We will illustrate the 
computational genomic analysis approach by reviewing the key findings on Ebola virus. 
 
 
Fig. 3. Potential -1 frameshift sites near the beginning of the major UGA-rich PPCR in the Ebola 
Zaire nucleoprotein (NP) mRNA, consisting of slippery sequences (underlined) and potential 
RNA PKs. The locations of these sites are indicated in Fig. 2 by A (beginning at position 1405 in 
GenBank #Ll1365) and B (beginning at position 1582). Codon-anticodon interactions of the P- 
and A-site tRNAs are shown schematically both before (below sequence) and after slippage 
(above sequence). Note that slippage on runs of C bases as in site A is known to occur in measles 
virus (33). 
 
Analysis of the Ebola sequence revealed two PPCRs in the -1 reading frame overlapping the 
major nucleoprotein NP gene, containing 17 and 11 UGA codons, respectively (Fig. 2). The first 
PPCR has excellent potential to be expressed by a ribosomal frameshift from the NP coding 
region owing to the presence of an "ideal" heptameric shift sequence (UUUCCCU, at site A in 
Fig. 2) and an RNA PK 8 bases downstream (Fig. 3A). Note that slippage on a run of Cs has 
been shown in measle virus (33). This potential frameshift site A comes very near the beginning 
of the PPCR, and could permit the formation of a fusion protein consisting of the N-terminal 314 
residues of NP fused to a 181 residue C-terminal module potentially containing 16 SeC residues, 
encoded in the -1 frame (bases 1411 to 1953 in GenBank #Ll1365; subsequent numbering refers 
to the same sequence). 
 
Downstream from the first site, there is a second near-ideal frameshift site (B in Fig. 2) and 
potential PK, also in the NP coding region beginning at position 1582 (Fig. 3B). This second site 
follows the sixth UGA codon in the PPCR, so a frameshift here would yield a potential 
selenoprotein module with only 11 SeC residues. These redundant frameshift sites could provide 
for either an increased probability of translating the selenoprotein module, or for two alternate 
forms of the NP fusion protein. 
 
Significantly, it has been shown that a pyrimidine base following a UGA codon (i.e., UGAY) 
will favor readthrough (e.g., by SeC insertion), whereas a purine base following a UGA codon 
(UGAR) will favor its function as a stop codon (43). Of the 17 UGA codons in PPCR1, all 
except for three near the 5'-end are followed by a pyrimidine base. Specifically, all 11 of the 
UGAs downstream of potential frameshift site B are UGAY, apparently programmed for 
readthrough, strongly favoring the possibility that this is a true selenoprotein gene. In this regard, 
it must be noted that the presence of a purine following a UGA does not completely rule out 
efficient translation as SeC, because in some cases, the requirement for a specific amino acid in 
the protein will dictate the necessity of a purine in this position, e.g., in GSH-Px, where there is a 
UGAG because there is a Gly following SeC in the protein sequence. 
 
Encoded between bases 2212 and 2598, there is a second UGA-rich PPCR overlapping the Ebola 
NP gene. It has 11 UGA codons over 129 residues (PPCR2 in Fig. 2). This PPCR lacks a start 
codon, but could be expressed from an edited or spliced RNA. RNA editing would be the more 
likely possibility in this case, because RNA editing is known to occur in at least one location in 
Ebola virus (44). Since there are no reports of Ebola replication and transcription in the nuclei of 
infected cells, RNA splicing seems improbable in Ebola. However, perhaps this should not be 
entirely ruled out, because there is precedent for nuclear replication/transcription and RNA 
splicing in a negative nonsegmented single-stranded RNA virus, in the case of Borna disease 
virus (45). Whether it is functional or not, there is a potential splice acceptor site very near the 
beginning of PPCR2, consisting of a CAGA sequence preceded by a pyrimidine-rich sequence 
and an upstream "CURAY" sequence (CUGAC). There are various potential splice donors in the 
large NP mRNA that could bring this region in-frame to the main NP PPCR or the upstream 
selenoprotein PPCR with 16 UGAs. Thus, we cannot rule out the possibility that nuclear 
transcription and splicing of this Ebola mRNA could occur under special circumstances, possibly 
in the unknown "reservoir" species that is the natural host for Ebola virus. 
 
Although the PPCRs overlapping the Ebola NP gene are the most striking owing to their high 
content of UGA codons, the analysis revealed several additional potential selenoprotein PPCRs 
overlapping other genes in the Ebola virus, including the vp24, vp30, vp35, and vp40 coding 
regions, all of which have potential SeC insertion sequences in their mRNAs (shown for vp30 
and vp35 in Fig. 4). Furthermore, on the Ebola minus strand genomic RNA, there are also 
potential SeC insertion sequences and several UGA-rich PPCRs (with up to nine UGAs), some 
with start codons in the context of Kozak-like sequences, and some potentially expressed from 
spliced genomic RNAs. Although we think it is rather improbable that any of these PPCRs on 
the minus strand are functional, expression of a protein encoded in a minus strand ORF has been 
proven in the case of HIV-1 (46). 
 
 
Fig. 4. Predicted RNA secondary structures for potential selenocysteine insertion sequences 
(AUG ... AAA ... UGA) in the Ebola virus RNA with potential to form the required stem-loop 
structures. A: In the 3'-untranslated region of the nucleoprotein mRNA, bases 2758-2836 in 
GenBank #L11365; E = -10.1 kcal/mol. B: At the 3'-end of the vp35 mRNA, bases 4094-4160; E 
= -13.4 kcal/mol. C: At the 3'-end of the vp30 mRNA, bases 9029-9087; E = -9.4 kcal/mol. Base 
pairs (shown as ladder rungs) marked by a slash are GU base pairs. Preliminary experimental 
results indicate that structure A is inactive in a standard assay for eukaryotic SECIS elements. 
Structures B and C have not yet been tested. 
 
If any of these potential UGA-rich PPCRs are expressed by specific SeC insertion mechanisms, 
then functional SECIS elements or something similar must exist in the viral RNA. We have 
identified a number of candidate genomic regions having the consensus sequence features of an 
SECIS element, as well as the potential to form the necessary RNA stem-loop structures; several 
of these are shown in Fig. 4. Of these, only candidate SECIS A has been tested; it is inactive in 
regard to ability to direct SeC insertion at a UGA codon in the human deiodinase gene 
(Nadimpalli et al., unpublished data). 
 
If no potential viral elements can be found capable of directing SeC insertion in known 
mammalian selenoprotein genes, several conclusions might be drawn about these UGA-rich 
overlapping PPCRs: 
 
1. They are nonfunctional artifacts, possibly evolved as Rima has suggested to cause 
termination of erroneously frameshifted protein chains (33). If so, they still might lead to 
low-level nonspecific SeC insertion as previously discussed (31). 
2. They are genuine selenoprotein genes that can be expressed in mammalian hosts, but a 
virally encoded cofactor is required for SeC insertion to take place. Elucidation of this 
possibility would require experimentation with live virus. 
3. They might be genuine selenoprotein genes that are expressed in a nonmammalian host 
(e.g., some insect) that may have a somewhat divergent SeC insertion apparatus that does 
not function in mammals. In that case, they would not be significant for pathogenesis in 
humans, unless they could still contribute to low-level nonspecific SeC insertion in some 
manner. 
 
These possibilities will require careful research to be eliminated from consideration. 
 
PATHOGENICITY AND POTENTIAL SELENOPROTEINS IN EBOLA 
 
One argument in favor of the possibility that these overlapping UGA-rich PPCRs may be 
significant for pathogenicity in humans involves differences between the Ebola Zaire and Ebola 
Reston strains. In the Ebola Reston strain, which was devoid of pathogenicity in the three 
humans that were infected, the major potential selenoprotein gene overlapping the NP gene in 
Ebola Zaire (PPCR1 in Fig. 2) appears to be truncated and is almost certainly inactive. In the 
Ebola Reston NP mRNA, the UGA-rich PPCRs are disrupted by non-UGA stop codons, there 
are fewer UGA codons, no analogous frameshift sites or PKs, and no candidate SECIS element 
in the 3'-UTR. Thus, there is no way that this potential selenoprotein gene could be specifically 
expressed in Ebola Reston. This is a definite major difference at the gene level between these 
strains, which have previously been considered to be very close genetically. This potential NP-
associated selenoprotein gene is also absent in Marburg virus, which also has a lower mortality 
rate than Ebola Zaire. However, both Marburg and Ebola Reston do have higher than expected 
densities of UGA codons in overlapping frames, suggesting that the nonspecific selenoprotein 
synthesis mechanism we have proposed might still contribute to Se depletion, blood clotting, and 
hemorrhagic symptoms (Ebola Reston was pathogenic in monkeys). 
 
CONCLUSIONS 
 
Selenium deficiency can weaken the immune system's ability to fight viral infection, permitting 
increased replication, rapid mutation, and facilitating the emergence of more virulent strains, as 
Beck et al. have suggested in the case of Coxsackie virus (40). In addition, virally encoded 
selenoproteins may be a novel contributing factor to increased viral pathogenicity under 
conditions of Se deficiency (31). Since any hypothetical selenoprotein genes would depend on 
the bioavailability of Se, a rare trace element, it is possible that the presence and activity of such 
genes in a virus would vary with geographical areas and thus be strain-specific (38). Specifically, 
long-term selenium deficiency in a host population could lead to the inactivation and loss of such 
genes. Although it would be difficult to predict the effects of such gene loss on the virulence of 
the strains involved, it could potentially be a novel factor contributing to differences in virulence 
between different viral strains. 
 
In the case of hemorrhagic fever viruses, the theoretical prediction of hypothetical selenoprotein 
genes is more convincing in light of the known role of Se in regulation of blood clotting 
discussed previously. The fact that hemorrhagic conditions are often associated with highly Se-
deficient diets in various species is also supportive of the hypothesis that Se might be involved in 
manifestations of hemorrhagic viral diseases. The possibility of nonspecific depletion of 
selenium is supported by the bias toward the usage of UGA codons in the -1 frame and the 
tendency of the virus to frameshift erroneously leading to translational slippage to other frames 
(33). Alternatively, as our anlysis of Ebola suggests, the prescence of UGA-rich PPCRs and the 
potential SECIS elements may indicate depletion of host Se by the programmed synthesis of 
specific selenoproteins. 
 
These hypothetical proteins, if present, may provide some type of antioxidant protection to the 
Ebola virions in a rapidly degenerating cellular environment. Because these PPCRs overlap the 
Ebola Zaire NP gene, they could only be expressed as an NP fusion protein. Therefore, it is 
possible that this Se module could be formed as an NP variant comprising a small fraction of the 
total NP present in virions. This is precisely equivalent to the possibility that some Coxsackie 
virus strains, like CVB3, may express a viral GSH-Px homolog as a fusion protein to the vp3 
capsid protein, permitting attachment of a GSH-Px module to the virion surface (31). In the same 
way that we proposed for CVB3 (31), attachment of an antioxidant module to the Ebola virion or 
its release as a soluble factor in the cell may provide various benefits to the virus, including 
defense against oxidative attack by the immune system. If this Ebola NP fusion selenoprotein is 
formed, incorporated Se may be detectable in Ebola Zaire virions in early infections before 
cellular stores of SeC become depleted. 
 
In conclusion, our analysis suggests that severe infection by Ebola and some other hemorrhagic 
fever viruses could produce an artificial and extreme Se depletion, resulting in extensive cellular 
damage owing to lipid peroxidation, combined with enhanced thrombosis. This suggests that 
indicators of Se status and lipid peroxidation ought to be examined in Ebola patients. This 
hypothetical disease mechanism is also consistent with the previously mentioned results of Hou 
et al. in which Se was used to treat an infectious viral hemorrhagic fever successfully (30). 
 
As Lavander and Beck and coworkers have proposed, there is considerable merit to the idea that 
factors like low Se in certain geographic regions may be contributing to the emergence of new 
and more virulent viral diseases (40). Our theoretical findings in regard to hemorrhagic fever 
viruses suggest that a viral requirement or utilization of Se, whether specific or nonspecific, may 
be a significant mechanism contributing to increased viral pathogenicity under conditions of Se 
depletion in human and animal populations. 
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